Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.09 CAD
Change Today +0.005 / 5.88%
Volume 69.9K
VRS On Other Exchanges
As of 1:30 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

verisante technology inc (VRS) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - C$0.19
52 Week Low
06/2/15 - C$0.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

verisante technology inc (VRS) Related Businessweek News

No Related Businessweek News Found

verisante technology inc (VRS) Details

Verisante Technology, Inc., a medical device company, develops and commercializes skin cancer detection systems. The company’s products include Verisante Aura, a spectroscopy system to aid in the detection of various skin cancers, including basal cell carcinoma, squamous cell carcinoma, melanoma, pre-cancerous lesions, and actinic keratosis; and Verisante Core for the detection of other types of cancer, including lung, gastro-intestinal, colorectal, and cervical cancers. It has a licensing agreement with the BC Cancer Agency for the manufacture, distribution, and sale of products based on patented skin cancer detection technology. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology, Inc. in January 2011. Verisante Technology, Inc. was founded in 2006 and is headquartered in Vancouver, Canada.

Founded in 2006

verisante technology inc (VRS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

verisante technology inc (VRS) Key Developments

Verisante Technology, Inc. Enters Amended Licensing Agreement with the BC Cancer Agency

Verisante Technology, Inc. announced that it has entered into an agreement that amends the licensing agreement originally entered into with the BC Cancer Agency ("BCCA") in July 2010. Under the more favorable terms of the Agreement, the Company continues to hold exclusive rights to use and sublicense BCCA's patented Raman technology, and to manufacture and sell AuraTM, a device for the detection of skin cancer, and CoreTM, a device for the detection of certain internal cancers in specified territories.

Verisante Technology, Inc. expected to report Q2 2015 results on August 31, 2015. This event was calculated by Capital IQ (Created on June 3, 2015).

Verisante Technology, Inc. expected to report Q2 2015 results on August 31, 2015. This event was calculated by Capital IQ (Created on June 3, 2015).

Verisante Technology, Inc. Obtains Mexican Approval to Market and Sell Aura

Verisante Technology, Inc. announced that it has received regulatory approval from the Federal Commission for Protection against Sanitary Risks (COFEPRIS), a division within the Mexican Ministry of Health, to market and sell Aura, a device for the detection of skin cancer, in Mexico. AuraTM is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information before making a final decision to biopsy. Basal cell and squamous cell skin cancers together make up about 96% of all skin cancers. While early detection of melanoma is critical due to its high mortality rate, it is also important to detect the most common skin cancers early in order to achieve the best patient outcomes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRS:CN C$0.09 CAD +0.005

VRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lucid Inc $0.65 USD 0.00
Guided Therapeutics Inc $0.06 USD +0.0029
MedX Health Corp C$0.09 CAD 0.00
MELA Sciences Inc $1.18 USD 0.00
Optiscan Imaging Ltd A$0.05 AUD -0.005
View Industry Companies

Industry Analysis


Industry Average

Valuation VRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 40.8x
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 41.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERISANTE TECHNOLOGY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at